Analysis of the dynamics of the nomenclature of medicines for the treatment of mental and behavioral disorders in the government program «Affordable Medicines»

Abstract

The number of patients with mental and behavioral disorders is growing rapidly in many countries around the world. Ukraine is not exception. The consequences of a full-scale war will cause severe mental trauma, as every 10th resident of our country now experiences depression, anxiety, and psychosomatic disorders that can last up to 10 years. All of this demonstrate the incredible relevance of comprehensive research to counteract the rapid increase in the incidence of mental and behavioral disorders, to find tools for effective treatment of this group of nosologies, and to find ways to improve the quality of life of patients. The aim of the study was to analyze the dynamics of the nomenclature of medicines for the treatment of mental and behavioral disorders in the Government Program «Affordable Medicines» for 2021–2024. To achieve this goal, we applied content analysis of regulatory legal acts using market research, as well as methods of comparative, statistical and economic analysis, as well as systematization and generalization. The results of the content analysis of all editions of the List of Medicinal Products Subject to Reimbursement under the State Guarantees for Medical Care of the Population revealed a stabilization of the number of international generic and brand names presented in the Government Program «Affordable Medicines» (9 and 65 respectively). However, given the martial law situation in Ukraine, the nomenclature of this group of drugs needs to be expanded. It was found that the range of medicinal products under study is dominated by domestically manufactured drugs, their segment is 54.5%, formed by 11 Ukrainian pharmaceutical companies. The foreign share is represented by 9 manufacturing countries, the most represented among which is India (16.9%). The number of medicinal products with full and partial reimbursement was analyzed and it was found that each of the international generic names under study has at least 1 product subject to full reimbursement. However, it is necessary to increase the number of medicines that are dispensed to patients free of charge for each international generic name, as a significant number of Ukrainians have mental and behavioral disorders and need greater economic accessibility to this particular group of drugs under martial law.